Tobacco Cessation Program
QuitLogix
QuitLogix® is a turnkey evidence-based tobacco cessation program for health plans, wellness companies and employer groups. The program uses evidence-based phone and online coaching methods as the foundation for behavioral change.
Our personalized coaching and online resources help people quit smoking, vaping and using other tobacco products. We have some of the highest success rates in the country, with a 40 percent responder quit rate and a 90 percent participant satisfaction rate.
QuitLogix is powered by National Jewish Health®, the nation’s leading respiratory hospital, and is at the forefront of developing comprehensive tobacco cessation programming online, over the phone and on mobile devices. We are the nation’s largest nonprofit provider of tobacco cessation services and over the past 17 years, we have helped more than 1.5 million people with their quit attempts.
QuitLogix is easy to implement, provides quick results and can be customized to meet your organization’s needs.
Our Tobacco Cessation Coaches (Coaches) are trained in the behavioral change model for smoking cessation. Listening is the key to our “meeting people where they are” approach. Our Coaches listen, understand, provide personal support and build relationships that promote quitting tobacco.
Included with QuitLogix
Program Participants Receive:
Five proactive, personalized telephone coaching sessions with an experienced Coach- Nicotine replacement therapy (NRT), if offered
- Access to mobile-friendly online tools including the online cost-savings calculator (a participant favorite) and the ability to chat online with a Coach in real-time are available at https://helpline.QuitLogix.org
- Text messaging and email support to help participants stay committed to their quit plan on the go
- Printed and electronic educational materials, including the industry-renowned My Quit Journey Workbook©
QuitLogix reaches populations across the United States with customized and culturally appropriate information developed for multiple audiences, including:
- African Americans
- Asian Americans
- American Indians
- LGBTQ+ Community
- Teens/Teens who vape
- People wanting to quit tobacco while coping with additional health matters including:
- Pregnancy
- COPD
- Diabetes
- High blood pressure
- Heart disease
- Behavioral health concerns
QuitLogix
Clinical Trials
Idiopathic Pulmonary Fibrosis (IPF) & GERD
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
Learn More- ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis)
- Atopic Dermatitis & Skin Infections
- BBT-877: Possible Treatment for Idiopathic Pulmonary Fibrosis
- BEACON-CF: Investigational mRNA Therapy for Cystic Fibrosis
- Biomarkers & Hypersensitivity Pneumonitis Progression
- Blood Test to Help Identify Cancer
- Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer?
- Creating Asthma Measurements through the MORRE Study
- Effects of Pregnancy for Cystic Fibrosis Patients
- Extensive Stage Small Cell Lung Cancer Combination Treatment
- Healthy Adults Needed for Beryllium Disease Study
- Healthy People Needed for Sarcoidosis Research
- Identifying Characteristics and Patterns of Asthma
- ILD & Early Rheumatoid Arthritis
- Immune Pathways & Development of Sarcoidosis
- Improving Treatment for IPF
- Investigational Gene Therapy for Adults with CF
- Link Between Rheumatoid Arthritis & Lung Disease
- Lung Cancer & COVID Infection
- Lung Injury from Military Deployment
- Mineral Dust & Lung Disease
- MyAI Registry for People with Adrenal Insufficiency
- New Trial Medication for Pulmonary Arterial Hypertension
- OCEAN Study for EGPA
- Possible New Inhaled Treatment Option for PH with ILD
- Potential New Treatment for Metastatic Lung Cancer
- Potential New Treatment for Metastatic Lung Cancer
- PRA023 for Systemic Sclerosis with Interstitial Lung Disease
- Predict and Prevent Lung Disease
- Predicting ILD from Hypersensitivity Pneumonitis
- Pulmonary Arterial Hypertension & increased dose of Opsumit
- Pulmonary Fibrosis & Genetic Factors
- RESOLVE-Lung Study for Pulmonary Sarcoidosis
- Silicosis Registry
- Skin Reactions to Cancer Immunotherapy
- Skin, Airway & Esophageal Epithelial Barriers in Youth
- SUNBEAM: Studying Allergy Development in Babies
- SUNRISE Trial for Oral Steroid Dependent Asthma
- Testing Blood’s Response to Foreign Substances
- Treating Deployment-Related Asthma with Supplements
- Understanding Allergy Development in Infants
- Understanding Reproductive Health Concerns in Men with CF
- Understanding Skin Problems from Eczema and Food Allergies
- XTMAB-16: A New Drug to Reduce Steroid Use in Sarcoidosis
Reasons to Choose National Jewish Health
- The leading respiratory hospital in the nation and the only one devoted fully to the treatment of respiratory and related illnesses
- Ranked #1 or #2 in Pulmonology by U.S. News & World Report for 26 consecutive years
- Ranked in the top 5% of hospitals in the nation by HCAHPS
- Physicians consistently recognized among the best in the nation by multiple services, including Best Doctors in America and Castle Connolly
- Among the top 6% of organizations funded for research by the NIH, providing patients access to hundreds of active clinical trials
- 124-year history of focus on care, research and education serving patients from around the world with lung, heart, immune and related disorders
Finding Care for Sarcoidosis in My Own Backyard
“The providers at National Jewish Health are problem solvers, not symptom solvers,” she stated. “They’re not willing to stop after fixing one problem, they look at the whole patient.”
Read More